The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The efficacy and safety of uproleselan plus chemotherapy versus chemotherapy alone in R/R AML
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents the results of an international Phase III trial (NCT03616470) evaluating the efficacy and safety of uproleselan combined with chemotherapy versus chemotherapy alone in relapsed/refractory (R/R) acute myeloid leukemia (AML). Dr DeAngelo notes that while the overall trial endpoint was negative, improved survival was seen in some subsets of patients, such as those with primary refractory disease or those undergoing transplantation. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Uproleselan is an E-selectin antagonist. The idea here is that you’re affecting the microenvironment. Some animal models as well as some in vitro studies have suggested that the addition of uproleselan to standard chemotherapy can improve chemotherapy response. So this was a randomized, large randomized international study of over 380 patients. Unfortunately, the overall endpoint of the study was negative...
Uproleselan is an E-selectin antagonist. The idea here is that you’re affecting the microenvironment. Some animal models as well as some in vitro studies have suggested that the addition of uproleselan to standard chemotherapy can improve chemotherapy response. So this was a randomized, large randomized international study of over 380 patients. Unfortunately, the overall endpoint of the study was negative. That is, uproleselan did not lead to an improved survival. However, there were some disease groups that did improve.
Number one, patients with primary refractory disease, those are patients who failed to get into remission or have a very early relapse within three months. Those patients did improve, have improved survival with uproleselan. Furthermore, patients who went to transplant and patients who achieved an MRD negative remission after induction, both of those groups seemed to do better with uproleselan, suggesting that there is some disease modification with the addition of uproleselan. However overall, unfortunately, the trial was negative.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen, Autolus, Blueprint, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, Takeda: Consultancy; Mt Sinai MPN Consortium: Other: Mt Sinai MPN Consortium; Daiichi-Sankyo, Fibrogen: Other: DSMB; AbbVie, Blueprint, GlycoMimetics, Novartis: Research Funding; Dana-Farber Cancer Institute: Current Employment.
